Heparin Market Report 2026

The heparin market size has grown strongly in recent years. It will grow from $10.23 billion in 2025 to $10.97 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to increase in cardiovascular surgeries, widespread use in dialysis procedures, proven clinical efficacy of UFH and LMWH, growth in inpatient hospital admissions, established reimbursement for anticoagulants.

The heparin market size is expected to see strong growth in the next few years. It will grow to $14.67 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to rising prevalence of venous thromboembolism, aging population with chronic disorders, expanding use of LMWH in outpatient care, growth of specialty pharmacies, increasing focus on preventive anticoagulation. Major trends in the forecast period include rising adoption of low molecular weight heparin, growing hospital-based anticoagulation protocols, increased demand for dialysis and cardiac care applications, shift toward pre-filled and ready-to-use injectables, expansion of online and retail pharmacy distribution.

The increasing number of surgical procedures is anticipated to drive the growth of the heparin market in the coming years. A surgical procedure is defined as a medical treatment or intervention that involves making incisions or employing minimally invasive techniques to access and treat tissues or organs within the body. As the volume of surgical procedures rises, the need for heparin - an anticoagulant used to prevent blood clot formation during and after surgery - also increases, thereby boosting demand for heparin and supporting market growth. For example, in February 2024, the American Academy of Facial Plastic and Reconstructive Surgery, a US-based non-profit organization, reported that nearly 83% of all medical procedures performed in 2023 were minimally invasive, while traditional surgical procedures accounted for the remaining 17%. Additionally, in 2023, the American Society of Plastic Surgeons, a US-based professional organization, stated that the total number of cosmetic minimally invasive procedures grew from 23.7 million in 2022 to 25.4 million in 2023. Consequently, the rise in surgical procedures is contributing to the expansion of the heparin market.

Leading companies operating in the heparin market are concentrating on the development of innovative solutions aimed at improving drug effectiveness, enhancing safety profiles, and minimizing side effects, while also investigating advanced delivery technologies and biosimilar development to address rising global demand. Heparin Sodium Chloride Injection is a sterile formulation that combines heparin, an anticoagulant used to prevent blood clotting, with sodium chloride, which helps maintain osmotic balance and solution stability. For example, in February 2024, B. Braun Medical Inc., a US-based medical company, introduced Heparin Sodium 2,000 Units in 0.9% Sodium Chloride Injection, offered in a 1,000 mL EXCEL IV container with a concentration of 2 units/mL. This launch represents the fifth addition to B. Braun’s heparin portfolio and is intended to support the varied requirements of healthcare facilities for this essential anticoagulant therapy.

In May 2023, Bioiberica, a Spain-based pharmaceutical ingredients and active pharmaceutical ingredient (API) manufacturer specializing in heparin, entered into a partnership with Vall Companys to form Biovall Heparin Science, a joint business initiative supported by an investment of $28.81 million (€25 million). Through this partnership, the companies seek to promote sustainable heparin manufacturing by adopting a circular economy approach that utilizes porcine intestinal mucosa co-products to produce crude heparin, while maintaining complete traceability, quality, and safety throughout the supply chain. Vall Companys is a Spain-based agri-food group and a leading producer of pork.

Major companies operating in the heparin market are Baxter International Inc., B. Braun Medical Inc., Dr. Reddy's Laboratories Ltd., Fresenius SE & Co. KGaA, Leo Pharma A/S, Aspen Pharmacare plc, Bioiberica SA, Biomedical Foscama Group, Biovet SA, Changzhou Qianhong Bio-pharma Co. Ltd., CSPC NBP Pharmaceutical Co. Ltd., Intas Pharmaceuticals Ltd., Nanjing King-friend Biochemical Pharmaceutical Co. Ltd., Opocrin Pharmaceuticals Ltd., Pfizer Inc., Pharma Action Ltd., Rovi Pharma Industrial Services Ltd., Sagent Pharmaceuticals Inc., Sanofi S. A., Shenzhen Hepalink Pharmaceutical Co. Ltd., Sichuan Deebio Pharmaceutical Co. Ltd., Teva Pharmaceuticals Industries Ltd., VAV Life Sciences Inc., Viatris Inc., Wanbang Biopharmaceuticals Co. Ltd., Wockhardt Ltd., Xinbai Pharmaceuticals Co. Ltd., Yino Pharma Co. Ltd.

North America was the largest region in the heparin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the heparin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the heparin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the heparin market by increasing costs associated with raw material sourcing, particularly porcine and bovine intestinal mucosa, and cross-border trade of active pharmaceutical ingredients. These impacts are most pronounced in LMWH and ULMWH segments and in regions dependent on imports, including parts of Asia-Pacific and Europe. Supply chain disruptions have pressured hospital procurement budgets and pricing strategies. However, tariffs have also encouraged regional manufacturing, supplier diversification, and improved traceability standards, supporting long-term supply security.

The heparin market research report is one of a series of new reports that provides heparin market statistics, including heparin industry global market size, regional shares, competitors with a heparin market share, detailed heparin market segments, market trends and opportunities, and any further data you may need to thrive in the heparin industry. This heparin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Heparin is an anticoagulant substance that inhibits the formation of blood clots. It is naturally produced by the liver, lungs, and other tissues in the human body, although it can also be manufactured in laboratory settings. To prevent or break down blood clots, heparin can be administered through injection into the muscle or directly into the bloodstream. It is extensively used in hospital settings to reduce the risk of excessive clotting during procedures such as cardiac surgery, extracorporeal circulation, and dialysis.

The primary forms of heparin include unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). The unfractionated heparin (UFH) market encompasses a category of rapidly acting anticoagulant drugs that inhibit clot development by interacting with antithrombin. Unfractionated heparin attaches to antithrombin and enhances its capacity to suppress two major clotting factors in the body - factor Xa and factor IIa - within minutes. These products are derived from bovine or porcine sources and are administered intravenously or subcutaneously. They are used to treat conditions such as venous thromboembolism, atrial fibrillation, renal impairment, coronary artery disease, and others. Distribution channels include hospital pharmacies, drug stores or retail pharmacies, as well as online pharmacies.

The heparin market consists of sales of enoxaparin, dalteparin, and nadroparin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.